Harnessing the power of antigen specific T-cell responses to improve vaccine development
Vaccine developers face many challenges related to understanding the immune response, including measuring the magnitude of response, determining the duration of the response and understanding efficacy.
Adaptive Biotechnologies has built a revolutionary immune medicine platform capable of profiling T-cell receptors (TCR) at high throughput in order to gain an in-depth understanding of cellular responses to vaccination. Using the Adaptive Immunosequencing assay, vaccine developers can measure the magnitude of T-cell response, monitor the duration of response, and correlate the response with efficacy. Immunosequencing may also be used to establish correlates of protection and of risk to better understand the level of cellular response needed to prevent infection and mitigate adverse events. When studying breakthrough infections, T-cell responses may help stratify patients based on disease severity.
Adaptive has also built a robust database linking TCRs to specific diseases. For some pathogens like SARS-CoV-2, RSV, and influenza, the database links specific TCRs to their cognate antigen. Taken together, Adaptive’s platform offers researchers at all stages of vaccine development the ability to characterize T-cell responses to inform vaccine efficacy and design more effective vaccines for current and emerging pathogens.
The content applies to those conducting vaccine research, including preclinical and clinical development with roles in pharmaceutical research, biotechnology and academia.
